By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Novartis: Better Margin Visibility Ex Sandoz. (NYSE:NVS)
News

Novartis: Better Margin Visibility Ex Sandoz. (NYSE:NVS)

News Room
Last updated: 2023/10/06 at 12:57 AM
By News Room
Share
5 Min Read
SHARE

Contents
The New NovartisConclusion and Valuation

Today at the Lab, we decided to recap Novartis’ latest and subsequent development (NYSE:NVS, OTCPK: NVSEF). As a reminder, on the 15th of September 2023, at the Extraordinary General Meeting, the company’s shareholders approved the Sandoz spin-off. Our internal team views this business separation positively, given that the companies have limited synergies. In addition, this spin-off will likely extrapolate more value embedded in the Novartis Innovative Medicine division and simultaneously create a global leader in Generics and Biosimilars. Yesterday was Sandoz’s D-day, and the company was listed with an IPO for a market value of $11.2 billion.

Looking at the press release details, Novartis completed “the Spin-off through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADRs), with each holder receiving one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs, held at the close of business on October 3, 2023.” The new listing was placed with the SIX Swiss Exchange under the ticker ‘SDZ,’ but there is already an ADR in the US (with an over-the-counter market). Here at the Lab, we are not new to commenting on this type of operation, as a reminder, last year, we reported Eurapi’s spin-off from Sanofi. This deal made Sanofi a more agile company and extrapolated the actual value of the company’s drug portfolio.

The New Novartis

In line with Sanofi, Novartis has now completed its business transformation to become a leader in innovative medicines. Indeed, the company is well-positioned for sustained top & bottom line growth thanks to four areas: Oncology, Neuroscience, Immunology, and Cardiovascular, Renal & Metabolic. Despite the spin-off, Novartis reaffirmed its 2023 outlook which was already raised in Q2 with the following: top-line sales forecasted to grow high single digits and EBIT to increase by low double digits to mid-teens. We can say that Novartis’s strategic plan unveiled in 2022 is almost completed. In addition, to support shareholders’ remuneration, the company confirmed its growing dividend per share policy, with no re-basing after the spin-off and its ongoing buyback, which is equal to $15 billion.

In our estimates, Novartis ex-Sandoz might experience a margin uplift. In Q2, we reported the following: “What we liked was the restructuring process, which started to be evident in H1 and reflected the company’s margin improvements”. Here at the Lab, despite LOEs on Entresto/Promacta, we anticipated a 2.5% CAGR revenue growth combined with a 3.7% core operating profit growth until 2028. How? Our internal team sees upside sales from Pluvicto (pre-chemo – Fig 1), Kisgali (adjuvant – Fig 2), Iptacopan (kidney disease with a readout planned in Q4 2023), and Scemblix (1L use with a submission and readout in 2024). In addition, Novartis has two existing technology platforms and three following platforms to increase internal R&D capabilities and add production capacity scale. At the moment, Novartis has a rich pipeline with approximately 150 projects in clinical development with a lower generics competition.

Pluvicto sales development

Pluvicto sales development

Fig 1

Kisgali sales development

Kisgali sales development

Fig 2

For the above reason, in a stand-alone model, excluding Sandoz, we anticipate a top-line sales CAGR of 3% until 2027 (Fig 3). In addition, despite the buyback, Novartis is actively looking for M&A. Recently, Novartis reached an agreement to acquire biopharmaceutical company Chinook Therapeutics for a total consideration of approximately $3.5 billion. With this acquisition, Novartis primarily intends to strengthen its pipeline in the field of kidney diseases (Fig 4).

Novartis sales

Novartis sales

Fig 3

Chinook Therapeutics transaction

Chinook Therapeutics transaction

Fig 4

Conclusion and Valuation

Although our internal team has a positive view of recent the company’s progress and potential positive catalyst thanks to a rich pipeline, we retain our preference for Roche, Lonza, and Grifols. Post Q2 results, we raised our visible period forecast which is in line with the company’s latest guidance; however, looking at the valuation, we reaffirmed our CHF 90 target price with a 2024 price earning of 14.5x (in line with our EU pharma peers). Our neutral rating is then confirmed.

Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

Read the full article here

News Room October 6, 2023 October 6, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Robert Kennedy’s touting of health ‘wearables’ sends medical device makers’ shares higher

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Europe should not go it alone on defence

Stay informed with free updatesSimply sign up to the Aerospace & Defence…

OpenAI and Jony Ive accused of trying to ‘bury’ rival start-up

The chief executive of a start-up that forced OpenAI and former Apple…

Wall Street firms emerge as top bidders for insurer Brighthouse

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Donald Trump lashes out at Israel and Iran in push to preserve ceasefire

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Robert Kennedy’s touting of health ‘wearables’ sends medical device makers’ shares higher

By News Room
News

Europe should not go it alone on defence

By News Room
News

OpenAI and Jony Ive accused of trying to ‘bury’ rival start-up

By News Room
News

Wall Street firms emerge as top bidders for insurer Brighthouse

By News Room
News

Donald Trump lashes out at Israel and Iran in push to preserve ceasefire

By News Room
News

Trump signals sanctions relief for China to buy Iran’s oil

By News Room
News

Jay Powell pushes back on calls for Federal Reserve rate cuts as soon as July

By News Room
News

EU readies retaliatory tariffs to secure better trade deal with Trump

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?